<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-C
REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ
INTERDEALER QUOTATION SYSTEM
FILED PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 AND RULE 13a-17
OR 15d-17 THEREUNDER
SEQUUS PHARMACEUTICALS, INC.
(Exact name of issuer as specified in charter)
960 Hamilton Court, Menlo Park, California 94025
(Address of principal executive offices)
Issuer's telephone number, including area code (415) 323-9011
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of five percent or more in the
number of shares outstanding:
1. Title of security Common Stock
2. Number of shares outstanding before the change 21,586,395
3. Number of shares outstanding after the change 25,486,395
4. Effective date of change October 30, 1995
5. Method of change: Specify method (such as merger, acquisition, exchange,
distribution, stock split, reverse split, acquisition
of stock for treasury, etc.)
Public offering
- -----------------------------------------------------------------------------
Give brief description of transaction Underwritten public offering and
issuance of 3,900,000 shares of Common Stock.
II. CHANGE IN NAME OF ISSUER
1. Name prior to change N/A
2. Name after change N/A
3. Effective date of charter amendment changing name N/A
4. Date of shareholder approval of change, if required N/A
Date November 1, 1995 /s/ DONALD J. STEWART
--------------------------------------
(Officer's signature and title)
